This article in the Drug and Therapeutics Bulletin (DTB) highlights the management of patient groups at increased risk of multidrug resistant tuberculosis (TB; defined as TB with resistance to both rifampicin and isoniazid), and extensively drug-resistant TB (defined as TB with resistance to rifampicin and isoniazid, and to at least one fluoroquinolone and

one second-line injectable agent such as amikacin or capreomycin).